STOCKHOLM, March 15, 2021 /PRNewswire/ -- CELLINK has
announced the launch of the BIO MDX™ Series, the next generation of
bioprinters designed for high-throughput biofabrication and
precision 3D bioprinting for biomedical manufacturing, including
biocompatible medical devices. Over the past 5 years, as
bioprinting has increasingly become the method of choice for
researchers in tissue engineering, cell culturing and regenerative
medicine, there has been a greater need for improved automation,
precision, and reproducibility across fabrication methods. With up
to six printheads, nanoliter and picoliter dispensing channels and
easy robotic integration, the BIO MDX and BIO MDX+ bioprinters have
been specifically designed to meet the demands of the
ever-advancing cell-based technologies.
The BIO MDX series is backed by more than 25 years of research
and development. Equipped with technology found on SCIENION
arrayers, these bioprinters represents the first cross business
systems for the CELLINK Group. Demonstrating a successful
integration of SCIENION's intellectual property with CELLLINK's
bioprinting expertise. This launch further illustrates our
commitment to the bioconvergence revolution by bringing forward new
technologies to solve the most pressing challenges in the life
sciences.
"Leveraging synergies across the group, this launch
represents an important step toward developing systems and
solutions that bring CELLINK closer to patient care and creating
the future of medicine. Biomedical manufacturing has desperately
needed improved technologies, and the BIO MDX Series provides just
that," says Héctor Martínez, CELLINK CTO.
"Bioprinting is increasing in stature within the life
sciences. In order to grow with our customers, it is essential that
we continue to push the industry forward and develop the latest and
greatest technologies. The BIO MDX represents exactly this and goes
a long way in strengthening what is already a robust bioprinting
product portfolio," says Artur
Aira, CELLINK Bioprinting Business Area Manager.
For further information, please contact:
Erik Gatenholm,
CEO
Phone (Sweden):
+46 73 267 00 00
Phone (US): +1
(650) 515 5566
Email:
eg@cellink.com
|
Gusten Danielsson,
CFO
Phone (Sweden): +46
70 991 86 04
Phone (US): +1 (857)
332 2138
Email:
gd@cellink.com
|
About CELLINK
Founded in 2016, CELLINK is the leading bioconvergence company
in the world that provides technologies, products and services to
create, understand and master biology. With a focus on the
application areas of bioprinting, multiomics, cell line
development, and diagnostics, the company develops and markets
innovative technologies that enable researchers in the life
sciences to culture cells in 3D, perform high-throughput drug
screening and print human tissues and organs for the medical,
pharmaceutical and cosmetic industries. CELLINK's products are
trusted by more than 1,800 laboratories, including ones at all the
top 20 pharmaceutical companies, are being used in more than 65
countries, and have been cited in more than 1,600 publications.
CELLINK is creating the future of medicine. CELLINK is listed on
the Nasdaq the Stockholm under
CLNK B. www.cellink.com
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/cellink-ab/r/cellink-launches-the-bio-mdx-series---a-scaled-up-revolution-in-biomedical-manufacturing,c3306652
The following files are available for download:
https://mb.cision.com/Main/14960/3306652/1387002.pdf
|
Release
|
https://news.cision.com/cellink-ab/i/cellink-product-launch-next-generation-bioprinter-bio-mdx,c2888783
|
CELLINK product
launch Next generation bioprinter BIO MDX
|